Rekor Systems (NASDAQ:REKR) Bolsa

Rekor Systems

Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.

Long Ideas

News

Markets

Media

Trading Ideas

CHRD

LRCX

REKR

SOUN

Jim Cramer llama a SoundHound AI una acción meme, su opinión sobre Lam Research y su favorita de energía, Enterprise Products Partners.

SoundHound AI y las recomendaciones de Cramer: ¿Inversión inteligente o especulación?

Advanced Environmental Recycling Technologies

AERT

AILE

CTXR

HONE

HSON

INTZ

KORE

LITM

NATR

PDYN

SLDP

VINC

WATT

Descubre los mayores ganadores y perdedores en el mercado previo tras movimientos impactantes en acciones clave hoy.

Las acciones de Vincerx Pharma (VINC) suben alrededor del 64%; 20 acciones que se mueven en premercado

Rekor Systems Inc

Rekor Systems Inc Warrants(08/11/2023)

<p>Barclays  analyst David Anderson   maintains TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Overweight and raises the price target from $45 to $51.</p>


Price Target

Analyst Ratings

Barclays Maintains Overweight on TechnipFMC, Raises Price Target to $51

<p><a href="https://www.bloomberg.com/news/articles/2025-07-25/american-air-s-new-airbus-jet-grounded-by-supply-chain-issue" title="https://www.bloomberg.com/news/articles/2025-07-25/american-air-s-new-airbus-jet-grounded-by-supply-chain-issue">https://www.bloomberg.com/news/articles/2025-07-25/american-air-s-new-airbus-jet-grounded-by-supply-chain-issue</a></p>


European Aeronautic Defence And Space Unsponsored

EADSY

'American Air's New Airbus Jet Grounded by Supply Chain Issue' - Bloomberg News

<p>Barclays  analyst Dan Levy   maintains Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) with a Equal-Weight and raises the price target from $115 to $120.</p>


Barclays Maintains Equal-Weight on Visteon, Raises Price Target to $120

<p>Barclays  analyst Brandt Montour   maintains Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Overweight and raises the price target from $100 to $101.</p>


Barclays Maintains Overweight on Wyndham Hotels & Resorts, Raises Price Target to $101

<p>DA Davidson  analyst Jeff Rulis   maintains Bridgewater Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWB#NASDAQ">BWB</a>) with a Buy and raises the price target from $18 to $20.</p>


DA Davidson Maintains Buy on Bridgewater Bancshares, Raises Price Target to $20

MCVT

Mill City Ventures III Shares Halted On Circuit Breaker To The Upside, Stock Now Up 211.3%

<p>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL&#xAE; gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, having exercise prices between $2.00 and $3.00 per share. Warrants to purchase 100,000 shares of common stock at the existing exercise price of $2.00 per share will be exercised at their existing exercise price of $2.00 per share and warrants to purchase 828,596 shares of common stock will be exercised at a reduced exercise price of $2.485 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statement on Form S-1 (No. 333-284381). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and offering expenses.</p>
<p>H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</p>
<p>In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $232,149 in the aggregate, which are included in the gross proceeds to the Company), the exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"). The new warrants will be exercisable for an aggregate of up to 1,857,192 shares of common stock, at an exercise price of $2.485 per share and will be immediately exercisable upon issuance and (i) will have a term of twenty-four months with respect to new warrants to purchase up to 1,538,596 shares of common stock and (ii) will have a term of five years with respect to new warrants to purchase up to 318,596 shares of common stock, in each case, following the effective date of the resale registration statement registering the shares of common stock issuable upon exercise of the new warrants.</p>
<p>The offering is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.</p>


Offerings

PHIO

Phio Pharmaceuticals Announces $2.5M In Gross Proceeds From Exercise Of 928,596 Warrants At $2.00 And $2.485 Per Share And Issues 1,857,192 New Unregistered Warrants At $2.485

<p>Crypto analyst Benjamin Cowen expects a bearish month for <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) in August, which could lead to fresh <a href="https://www.benzinga.com/money/ethereum-eth-price-predictions#:~:text=Maximum%20Prediction%3A%20%244%2C783,regulatory%20developments%20could%20moderate%20prices.">lows for altcoins</a>.</p>
<p><strong>What Happened: </strong>In a July 21 <a href="https://www.youtube.com/watch?v=kfg7dNU7TJk">podcast</a>, Cowen maintains that altcoins remain elevated when measured against BTC, citing his custom indicator, &#8220;Total3 minus USDT divided by Bitcoin&#8221;, which suggests further downside for altcoins. </p>
<p>According to Cowen, even when Bitcoin dominance hit 60% in October 2024, altcoins were still trading 27%–28% above their historical range lows.</p>
<p>&#8220;It didn't make sense for that to be the top of Bitcoin dominance because altcoin/BTC pairs were still well above their range lows,&#8221; he said.</p>
<p>While Cowen sees <strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) as likely having bottomed vs BTC, he warns most altcoins are still bleeding heavily, down over 42% vs ETH since April. </p>
<p>Given the risk-reward profile, Cowen says he prefers ETH over smaller-cap altcoins, calling it a lower-risk, higher-upside play in the current macro setup.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46627515/bitcoin-slips-below-117000-on-whale-selling-ethereum-xrp-hold-steady">Bitcoin Slips Below $117,000 On Whale Selling, Ethereum, XRP Hold Steady</a></strong></p>
<p><strong>What's Next: </strong>Cowen emphasizes August&#8217;s seasonal weakness, pointing out that Bitcoin has historically dropped between 12%–14% in August for the past three years. </p>
<p>This could pressure both BTC and altcoins, although he sees BTC dominance climbing sharply from late August onward.</p>
<p>He expects the combined dominance of BTC and ETH, currently around 73%, to rise to near 85%, especially if altcoins underperform into Q4. </p>
<p>Even if altcoins rally briefly, as in 2017, he expects them to revisit cycle lows around 0.25 on his custom metric by October.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46612914/bitcoin-could-go-to-300000-before-great-depression-crisis-traders-argue">Bitcoin Could Go To $300,000 Before &#8216;Great Depression&#8217; Crisis, Traders Argue</a></strong></li>
</ul>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Bitcoin Could See Bearish August, Analyst Says—What Does It Mean For Ethereum, XRP, Solana?

<p>DA Davidson  analyst Jeff Rulis   maintains Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) with a Neutral and raises the price target from $17 to $19.</p>


OSBC

DA Davidson Maintains Neutral on Old Second Bancorp, Raises Price Target to $19

<p>DA Davidson   maintains QCR Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) with a Buy and raises the price target from $80 to $87.</p>


QCRH

DA Davidson Maintains Buy on QCR Hldgs, Raises Price Target to $87

<p><strong>Rocket Pharmaceuticals, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>), a firm focused on developing cardiovascular gene therapy, announced a strategic corporate reorganization to <a href="https://www.benzinga.com/general/biotech">extend its runway</a>.</p>
<p>The restructuring and reprioritization initiative <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46597099/rocket-pharmaceuticals-announces-strategic-corporate-reorganization-and-pipeline-prioritization-of" rel="noreferrer noopener">focuses Rocket&#8217;s resources</a> on the adeno-associated virus (AAV) cardiovascular platform, comprised of clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), and BAG3-associated dilated cardiomyopathy (BAG3-DCM), as well as submitting the completed responses to the CRL for KRESLADI (formerly RP-L201) for severe leukocyte adhesion deficiency-I (LAD-I).</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45655674/rocket-pharmas-gene-therapy-future-clouded-by-regulatory-uncertainty" target="_blank" rel="noreferrer noopener">Rocket Pharma&#8217;s Gene Therapy Future Clouded By Regulatory Uncertainty</a></strong></p>
<p>The transition reflects the company&#8217;s focus on its late-stage AAV pipeline, a strategy previously announced in January 2025.</p>
<p>The company will reduce its workforce by approximately 30%. Along with other planned cost-saving initiatives, Rocket expects this will reduce it&#8217;s 12-month operating expenses by nearly 25%.</p>
<p>Rocket anticipates that its existing cash resources will fund operations into the second quarter of 2027.</p>
<p>Based on business and strategic priorities and as part of its realignment, Rocket anticipates delays associated with the Fanconi Anemia (FA; RP-L102) and Pyruvate Kinase Deficiency (PKD; RP-L301) programs.</p>
<p>Regulatory approval of RP-L102 in 2026 is unlikely.</p>
<p>In May, the FDA placed a clinical hold on the company&#8217;s Phase 2 pivotal trial of RP-A501, investigational gene <a href="https://www.benzinga.com/25/05/45621333/rocket-pharma-reports-patient-death-in-rare-disease-gene-therapy-trial-fda-puts-clinical-hold" target="_blank" rel="noreferrer noopener">therapy for Danon disease</a>.</p>
<p><strong>Analyst Reaction</strong>: Bank Of America (BofA) Securities&#8217; Jason Zemansky downgraded Rocket from Buy to Neutral and reduced the <a href="https://www.benzinga.com/quote/RCKT/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $9 to $4</a>.</p>
<p>The analyst states that the gene therapy for Danon disease was the primary driver of Rocket Pharmaceuticals&#8217; performance. But after recent high-profile failures in the gene therapy space, investor confidence has weakened.</p>
<p>BofA writes the company is indirectly admitting that the outlook for its lead program remains uncertain in the near term. While the cost savings may be beneficial in the long run, near-term gains appear to be limited.</p>
<p>Without a clear timeline and with continued concerns around <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46634492/sarepta-gets-thumbs-down-from-regulators-regarding-elevidys-gene-therapy" target="_blank" rel="noreferrer noopener">the gene therapy class</a>, investors may remain cautious.</p>
<p><strong>Price Action:</strong> RCKT stock is down 2.80% at $3.12 at the last check on Friday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/news/health-care/25/07/46629899/eli-lillys-early-alzheimers-drug-recommended-for-approval-by-european-drug-regulators-panel" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Early Alzheimer&#8217;s Drug Recommended For Approval By European Drug Regulator&#8217;s Panel</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>



Analyst Color

Biotech

Downgrades

Health Care

Movers

General

RCKT

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

<p>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) will release its quarterly earnings report on Monday, 2025-07-28. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Geovax Labs to report an <strong>earnings per share</strong> (EPS) of $-0.41.</p>
<p>Anticipation surrounds Geovax Labs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.21 in the last quarter, leading to a 2.09% increase in the share price on the following day.</p>
<p>Here's a look at Geovax Labs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.66</td>
<td>-0.79</td>
<td>-1.48</td>
<td>-4.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.45</td>
<td>-0.30</td>
<td>-0.91</td>
<td>-1.99</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-13.0%</td>
<td>-17.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753470129_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Geovax Labs were trading at $0.8125 as of July 24. Over the last 52-week period, shares are down 65.66%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GOVX/earnings"><strong>To track all earnings releases for Geovax Labs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

GOVX

Earnings Preview For Geovax Labs

<p>Provident Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROV#NASDAQ">PROV</a>) will release its quarterly earnings report on Monday, 2025-07-28. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Provident Finl Hldgs to report an <strong>earnings per share</strong> (EPS) of $0.30.</p>
<p>Investors in Provident Finl Hldgs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.04, leading to a 1.27% increase in the share price the following trading session.</p>
<p>Here's a look at Provident Finl Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.24</td>
<td>0.25</td>
<td>0.24</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.28</td>
<td>0.13</td>
<td>0.28</td>
<td>0.28</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>1.0%</td>
<td>-0.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753470118_0.png" alt="eps graph" /></p>
<h3>Provident Finl Hldgs Share Price Analysis</h3>
<p>Shares of Provident Finl Hldgs were trading at $15.5 as of July 24. Over the last 52-week period, shares are up 13.9%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PROV/earnings"><strong>To track all earnings releases for Provident Finl Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PROV

What to Expect from Provident Finl Hldgs's Earnings

<p><strong>Ekso Bionics Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) is set to give its latest quarterly earnings report on Monday, 2025-07-28. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Ekso Bionics Holdings will report an <strong>earnings per share</strong> (EPS) of $-1.20. </p>
<p>Ekso Bionics Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.15, leading to a 9.11% drop in the share price the following trading session.</p>
<p>Here's a look at Ekso Bionics Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.65</td>
<td>-1.2</td>
<td>-1.5</td>
<td>-1.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.80</td>
<td>-2.1</td>
<td>-1.5</td>
<td>-1.95</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-9.0%</td>
<td>-1.0%</td>
<td>-15.0%</td>
<td>-28.999999999999996%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753470106_0.png" alt="eps graph" /></p>
<h3>Performance of Ekso Bionics Holdings Shares</h3>
<p>Shares of Ekso Bionics Holdings were trading at $4.72 as of July 24. Over the last 52-week period, shares are down 78.81%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Observations about Ekso Bionics Holdings</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ekso Bionics Holdings.</p>
<p>Analysts have given Ekso Bionics Holdings a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $4.0, indicating a potential 15.25% downside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of PAVmed and Co-Diagnostics, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for PAVmed, with an average 1-year price target of $19.0, suggesting a potential 302.54% upside.</li>
<li>Analysts currently favor an Buy trajectory for Co-Diagnostics, with an average 1-year price target of $10.0, suggesting a potential 111.86% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for PAVmed and Co-Diagnostics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ekso Bionics Holdings</td>
<td>Buy</td>
<td>-10.14%</td>
<td>$1.81M</td>
<td>-24.54%</td>
</tr>
<tr>
<td>PAVmed</td>
<td>Buy</td>
<td>-99.21%</td>
<td>$-28K</td>
<td>274.23%</td>
</tr>
<tr>
<td>Co-Diagnostics</td>
<td>Buy</td>
<td>-80.11%</td>
<td>$28.69K</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ekso Bionics Holdings ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks at the top for Return on Equity.</p>
<h3>Discovering Ekso Bionics Holdings: A Closer Look</h3>
<p>Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.</p>
<h3>Ekso Bionics Holdings's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Ekso Bionics Holdings's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-10.14%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-92.36%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ekso Bionics Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-24.54%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-11.55%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Ekso Bionics Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.44</strong>.</p>
<p><a href="https://www.benzinga.com/quote/EKSO/earnings"><strong>To track all earnings releases for Ekso Bionics Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


EKSO

Preview: Ekso Bionics Holdings's Earnings

<p>Ranger Energy Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) will release its quarterly earnings report on Monday, 2025-07-28. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Ranger Energy Services to report an <strong>earnings per share</strong> (EPS) of $0.10.</p>
<p>Ranger Energy Services bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<p>Here's a look at Ranger Energy Services's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td></td>
<td>0.29</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.03</td>
<td>0.25</td>
<td>0.39</td>
<td>0.21</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-12.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>
</p>
<h3>Performance of Ranger Energy Services Shares</h3>
<p>Shares of Ranger Energy Services were trading at $12.34 as of July 24. Over the last 52-week period, shares are up 10.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Ranger Energy Services</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ranger Energy Services.</p>
<p>Ranger Energy Services has received a total of 1 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $13.0, the consensus suggests a potential 5.35% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Natural Gas Services Gr, Oil States International and DMC Glb, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Natural Gas Services Gr, with an average 1-year price target of $33.0, suggesting a potential 167.42% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Oil States International, with an average 1-year price target of $5.5, suggesting a potential 55.43% downside.</li>
<li>Analysts currently favor an Neutral trajectory for DMC Glb, with an average 1-year price target of $8.5, suggesting a potential 31.12% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Natural Gas Services Gr, Oil States International and DMC Glb, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranger Energy Services</td>
<td>Neutral</td>
<td>-1.24%</td>
<td>$9.20M</td>
<td>0.22%</td>
</tr>
<tr>
<td>Natural Gas Services Gr</td>
<td>Buy</td>
<td>12.13%</td>
<td>$15.62M</td>
<td>1.88%</td>
</tr>
<tr>
<td>Oil States International</td>
<td>Neutral</td>
<td>-4.38%</td>
<td>$25.24M</td>
<td>0.45%</td>
</tr>
<tr>
<td>DMC Glb</td>
<td>Neutral</td>
<td>-4.54%</td>
<td>$41.20M</td>
<td>0.29%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ranger Energy Services ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit and Return on Equity.</p>
<h3>All You Need to Know About Ranger Energy Services</h3>
<p>Ranger Energy Services Inc is a provider of onshore high-specification (high-spec) well service rigs, wireline services, and additional processing solutions and ancillary services in the United States. It offers a range of well-site services to U.S. exploration and production (E&amp;P) companies that are fundamental to establishing and enhancing the flow of oil and natural gas throughout the productive life of a well. The segments of the group are High Specification Rigs, Wireline Services and Processing Solutions, and Ancillary Services, of which key revenue is derived from the High Specification Rigs segment.</p>
<h3>Financial Insights: Ranger Energy Services</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Ranger Energy Services's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-1.24%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Ranger Energy Services's net margin excels beyond industry benchmarks, reaching <strong>0.44%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>0.22%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Ranger Energy Services's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.16%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.08</strong>, Ranger Energy Services adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/RNGR/earnings"><strong>To track all earnings releases for Ranger Energy Services visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RNGR

Preview: Ranger Energy Services's Earnings

<p>Bankwell Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWFG#NASDAQ">BWFG</a>) will release its quarterly earnings report on Monday, 2025-07-28. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Bankwell Finl Gr to report an <strong>earnings per share</strong> (EPS) of $0.85.</p>
<p>The market awaits Bankwell Finl Gr's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.14 in the last quarter, leading to a 4.93% increase in the share price on the following day.</p>
<p>Here's a look at Bankwell Finl Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.73</td>
<td>0.65</td>
<td>-0.08</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.87</td>
<td>0.32</td>
<td>0.24</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753470083_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Bankwell Finl Gr were trading at $36.92 as of July 24. Over the last 52-week period, shares are up 40.53%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BWFG/earnings"><strong>To track all earnings releases for Bankwell Finl Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BWFG

Examining the Future: Bankwell Finl Gr's Earnings Outlook

<p><a href="https://www.ft.com/content/3c8cf028-e49f-4ac3-8d95-6f6178cf2aac" title="https://www.ft.com/content/3c8cf028-e49f-4ac3-8d95-6f6178cf2aac">https://www.ft.com/content/3c8cf028-e49f-4ac3-8d95-6f6178cf2aac</a></p>


AMZN

'AI start-up Anthropic seeks to double valuation to over $150bn in talks with Mideast funds; Final Terms Have Not Been Fixed, Anthropic Was Expected To Raise At Least $3B, With One Adding The Round Could Reach Up To $5B' - Financial Times

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Albemarle</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALB, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Albemarle.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 42%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $251,812, and 9 are calls, for a total amount of $600,223.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $140.0 for Albemarle over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Albemarle's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Albemarle's whale trades within a strike price range from $60.0 to $140.0 in the last 30 days. </p>
<h3>Albemarle 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753470074_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$1.96</td>
<td>$1.62</td>
<td>$1.82</td>
<td>$140.00</td>
<td>$127.4K</td>
<td>446</td>
<td>700</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$15.9</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$85.00</td>
<td>$124.8K</td>
<td>54</td>
<td>100</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$5.6</td>
<td>$5.45</td>
<td>$5.6</td>
<td>$80.00</td>
<td>$112.0K</td>
<td>2.7K</td>
<td>227</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$0.91</td>
<td>$0.75</td>
<td>$0.91</td>
<td>$100.00</td>
<td>$91.0K</td>
<td>1.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$12.2</td>
<td>$12.15</td>
<td>$12.2</td>
<td>$95.00</td>
<td>$89.0K</td>
<td>121</td>
<td>99</td>
</tr>
</tbody>
</table>
</p>
<h3>About Albemarle</h3>
<p>Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.</p>
<p>Following our analysis of the options activities associated with Albemarle, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Albemarle Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,839,208, with ALB's price up by 0.58%, positioned at $84.67.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<h3>Expert Opinions on Albemarle</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $73.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS downgraded its action to Sell with a price target of $57.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Albemarle, which currently sits at a price target of $75.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Albemarle with a target price of $87. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Albemarle, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Albemarle Unusual Options Activity For July 25

<p>Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) will release its quarterly earnings report on Monday, 2025-07-28. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Seven Hills Realty Trust to report an <strong>earnings per share</strong> (EPS) of $0.33.</p>
<p>Anticipation surrounds Seven Hills Realty Trust's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.03, leading to a 6.47% increase in the share price on the subsequent day.</p>
<p>Here's a look at Seven Hills Realty Trust's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.31</td>
<td>0.33</td>
<td>0.35</td>
<td>0.33</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.34</td>
<td>0.33</td>
<td>0.36</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-0.0%</td>
<td>-8.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753470072_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Seven Hills Realty Trust were trading at $10.81 as of July 24. Over the last 52-week period, shares are down 20.22%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SEVN/earnings"><strong>To track all earnings releases for Seven Hills Realty Trust visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SEVN

A Look Ahead: Seven Hills Realty Trust's Earnings Forecast

<p>Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $128.4, a high estimate of $140.00, and a low estimate of $110.00. This upward trend is evident, with the current average reflecting a 6.12% increase from the previous average price target of $121.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753470071_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Pinnacle Finl Partners. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Benjamin Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$125.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Benjamin Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$123.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pinnacle Finl Partners. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pinnacle Finl Partners compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Pinnacle Finl Partners's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Pinnacle Finl Partners's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PNFP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Pinnacle Finl Partners analyst ratings.</strong></a></p>
<h2>All You Need to Know About Pinnacle Finl Partners</h2>
<p>Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.</p>
<h3>A Deep Dive into Pinnacle Finl Partners's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Pinnacle Finl Partners's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>17.52%</strong> as of 30 June, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Pinnacle Finl Partners's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>32.32%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Pinnacle Finl Partners's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.43%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Pinnacle Finl Partners's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.28%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Pinnacle Finl Partners's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.34</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PNFP

Expert Outlook: Pinnacle Finl Partners Through The Eyes Of 10 Analysts

Press Releases

Rekor's Vehicle Insite Application Deployed to Study Electric Vehicle Movement Across 90 Sites in the Phoenix Metropolitan Area

Rekor Systems Provides Guidance on Financial Results and Updates on Operational and Management Realignments

Rekor Systems Reports Strong 2024 Financial Results Highlighted by Record Revenue and Significant Operational Improvements

SoundThinking Enhances PlateRanger Investigative Capabilities with Integrations into SafetySmart Platform and Partner Technologies, Providing a 'Force Multiplier'

Rekor Systems to Announce First Quarter Fiscal 2025 Results

Rekor Systems Reports First Quarter 2025 Financial Results

Rekor Systems Selected for Statewide Texas DOT Contract to Deploy Rekor Command® Platform

Sun Belt State Transportation Agency to Deploy 150 Rekor Discover® Systems Under Rekor's Data-as-a-Service Model

Central Texas Regional Mobility Authority Extends Rekor Command® Contract in $1.4 Million Agreement to Enhance Toll Road Traffic Operations

Rekor Systems to Announce Second Quarter Fiscal 2025 Results

SSTI

AudioEye

CoreCard

Cheetah Mobile Inc. American Depositary Shares, each representing fifty (50) Class A Ordinary Shares

Comments

Rekor Systems

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL